Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats

• Автори: Wenchao Zhang (Автор), Jianwei Liu (Автор), Yang Fu (Автор), Huifang Ji (Автор), Zheyan Fang (Автор), Wanming Zhou (Автор), Huimin Fan (Автор), Yingxuan Zhang (Автор), Yan Liao (Автор), Ting Yang (Автор), Xiaolin Wang (Автор), Wanwan Yuan (Автор), Xiaoshu Chen (Автор), Yi-fei Dong (Автор)
• Формат: Книга
• Опубліковано: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Previous studies have confirmed the clinical efficacy of sacubitril/valsartan (Sac/Val) for the treatment of heart failure with reduced ejection fraction (HFrEF). However, the role of Sac/Val in heart failure with preserved ejection fraction (HFpEF) remains unclear. Sac/Val is a combination therapeu...